VBL Therapeutics to Report Full-Year 2016 Financial Results on March 27

TEL AVIV, Israel, March 02, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Monday, March 27, 2017 at 8:30am Eastern Time to report fourth quarter and full-year ended December 31, 2016 financial results.

Monday, March 27th @ 8:30am Eastern Time
Domestic:888-727-7622 
International: 913-312-0384 
Conference ID:8563883 
Webcast:http://edge.media-server.com/m/p/npmjtb62
 
Replays, available through April 10, 2017: 
Toll Free:844-512-2921 
International:412-317-6671 
Conference ID:8563883 

About VBL 
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >200 cancer patients and we have observed its efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 pivotal trial for recurrent Glioblastoma, conducted under an FDA Special Protocol Assessment (SPA).

CONTACT: INVESTOR CONTACT:
Michael Rice
LifeSci Advisors, LLC
(646) 597-6979

Ads